A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of
Epicutaneous lmmunotherapy with DBV712 250 ?g in 4-7-year-old Children with Peanut Allergy
(VITESSE)
This is a 12-month, Phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of daily DBV712 250 μg in peanut-allergic children aged 4-7 years.
